Cellink is a Swedish biotechnology company founded in 2016 by Erik Gatenholm, headquartered in Stockholm. The company specializes in advanced 3D cell culture and bioprinting technologies that enable researchers, pharmaceutical companies, and contract research organizations to conduct more physiologically accurate drug discovery, toxicology testing, and regenerative medicine research. As a publicly listed company on Nasdaq since 2020, Cellink provides bioprinting systems and bioink materials that create functional human tissue models replicating native conditions more closely than traditional 2D cultures. The company serves the global pharmaceutical, cosmetics, and academic research sectors with technologies aimed at improving drug efficacy testing, reducing animal research reliance, and accelerating personalized medicine development.
42 open now, 42 first appeared in the last 30d.